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Abstract
Obstructive sleep apnea (OSA) syndrome has emerged as a major public health prob-
lem because of its high prevalence amongst middle-aged, obese men as well as in 
lean individuals and women. It has been suggested that obesity’s role in the genesis of 
sleep apnea is rather through its metabolic activity than a purely anatomic/mechani-
cal impact. Recent studies demonstrate that circulating levels of adipokines, adipose 
tissue-derived secretory proteins, are altered in patients with OSA syndrome. For in-
stance, leptin level is increased, whereas that of adiponectin decreased in OSA, and 
these changes can be reversed by treatment of apnea/hypopnea episodes. Adipokine 
pro!le seems to change towards a proin"ammatory pattern that may also contribute 
to OSA-related cardiometabolic diseases. The mechanisms of adipose dysfunction in 
OSA includes hypoxia, oxidative stress and increased sympathetic nervous activity, in-
cluding alterations in the circulating  levels of the neurotrophins nerve growth factor 
(NGF) and brain-derived neurotrophic factor (BDNF). In e#ect, reversing hypoxia and 
attenuating oxidative stress and in"ammation through adipokine- and NGF/BDNF-
targeted pharmacology may provide novel therapeutic opportunities in patients with 
OSA syndrome.  
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Introduction
Obstructive sleep apnea (OSA) syn-
drome is characterized by recur-
rent episodes of partial (hypopnea) 
or complete interruption (apnea) in 
breathing during sleep due to air-
way collapse in the pharyngeal re-
gion. Obstructive sleep apnea and its 
cardiometabolic consequences have 
been widely explored in many studies. 
Briey, OSA has emerged as a major 
public health problem because of its 
high prevalence amongst middle-
aged, obese men as well as in lean in-
dividuals and women. Although sleep 
apnea has been almost always treated 
as a local obstruction of the upper 
airways, its systemic aspects in terms 
of cardiometabolic consequences are 
now acknowledged. Recently, a num-
ber of associated features of OSA 
have led researchers to consider the 
possibility that sleep apnea is a mani-
festation of the metabolic syndrome 
(dyslipidemia, dyscoagulation, hyper-
tension and insulin resistance) and its 
cardiovascular sequelae (1). Interest-
ingly, it has been suggested that obesi-
ty’s role in the genesis of OSA is rather 
through its metabolic activity than a 
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purely anatomic/mechanical impact (2).
 Human body comprises two major types of adipose tissue 
namely brown and white adipose tissue (BAT and WAT, respec-
tively). White adipose tissue serves as the main energy reser-
voir and the source of protein signaling molecules collectively 
termed adipokines (reviewed in 3-5, 7), whereas BAT is spe-
cialized for heat production by non-shivering thermogenesis. 
Over the past two decades, our understanding of the physiology 
of WAT changed by de!nition of its secretory products which 
are collectively termed adipokines. Among them, there are cy-
tokines such as leptin, tumour necrosis factor-alpha (TNF-α) 
and interleukins, also various growth factors. Adipokines also 
include proteins involved in the regulation of lipid and glucose 
homeostasis (adiponectin, TNF-α, resistin, retinol binding pro-
tein, NGF, BDNF), blood pressure (renin, angiotensin), vascular 
hemostasis (plasminogen activator inhibitor-1) and angiogen-
esis (vascular endothelial growth factor, NGF).   
 Data from translational and clinical studies support the no-
tion that OSA is associated with altered circulating levels of 
adipokines. It is also well established that obesity is a leading 
pathophysiologic factor of OSA. Accordingly, impaired adipose 
tissue physiology may be the link between OSA and its cardio-
metabolic consequences. 
 #e present review will focus on endocrine and paracrine sig-
nals generated by adipose tissue cells (adipocytes and associated 
stromal vascular cells), with special reference to their possible 
involvement in the pathobiology of OSA syndrome.
Adipocytes and other adipose cells  are examples of en-
docrine cells
Adipocytes continue their lives within a connective tissue ma-
trix and are adapted to store and release energy. #e diameter 
of an adipocyte may vary from 20 to 200 μm. #e nucleus is 
pushed to the periphery of the cell, as approximately 90% of the 
cell volume comprises of lipid droplets (liposomes). In the past, 
the adipocyte has been considered to be only a passive tissue for 
the storage of excess energy in the form of fat droplets. However, 
we now know that WAT is a central player of a communicative 
team broadcasting autocrine, paracrine, and endocrine signals 
(reviewed in 3-5). Besides its major role in regulating energy 
balance, WAT also plays a dynamic role in other physiologi-
cal processes including inammation, immunity, angiogenesis, 
haemostasis, reproduction, and memory and learning. Follow-
ing the identi!cation of leptin encoded in ob/ob gene of white 
adipocytes (6), a critical change occurred in perspective on the 
physiological role of WAT. Up to now, more than 200 di&erent 
adipocyte-derived secretory molecules are identi!ed (7). In a 
quantitative manner, the most important secretion of adipocytes 
is fatty acids, of which there is a considerable amount of net re-
lease at times of negative energy balance, particularly fasting and 
during acute exposure to cold. Other adipokines may be classi!ed 




, IL-6, IL-10, TGF
b
, IL-17, IL-18); 
acute phase proteins such as C-reactive protein (CRP), hapto-
globin, serum amyloid A; metabolism- and inammation-related 
mediators (adiponectin, visfatin, resistin, NGF, BDNF) (3-7).
Adipokines and obstructive sleep apnea
Leptin
In the beginning of 2000s, several studies reported increased leptin 
levels in OSA patients (8-10). #e severity of OSA was associated 
with increasing levels of leptin, and the positive correlation be-
tween the disease severity and leptin level was independent of age 
and body mass index (10). #e later studies investigated the e&ects 
of treatment on circulating leptin levels. Both continuous positive 
airway pressure (CPAP) therapy (11-13) and surgical treatment 
(14) reduced leptin levels without a signi!cant change in body 
weight. #is suggests other mechanisms rather than fat mass may 
contribute to the increased leptin in sleep apnea patients. For in-
stance, pathophysiologic changes including hypoxemia, increased 
sympathetic activity, and sleep fragmentation in sleep apnea may 
lead to elevated leptin levels. Hypercapnia in patients  with OSA 
syndrome was associated with increase levels of circulating lep-
tin (15). #e physiological explanation for CPAP-induced decline 
in leptin levels has not been fully elucidated. Nevertheless, there 
may be some explanations including reduced muscle sympathetic 
nerve activity (16) together with reduced level of stress (17), and a 
change in insulin responsiveness (18) following CPAP treatment. 
#ese explanations suggest that increased leptin production may 
be a consequence of OSA rather than being a hyperleptinemia-
induced state. Besides, leptin may be, in part, responsible for 
development of several complications such as hypertension and 
cardiovascular disease in sleep apnea patients (19).
Adiponectin
Adiponectin, a multifunctional adipokine produced mainly by 
adipocytes, stimulates fatty acid oxidation, suppresses inam-
matory responses and hepatic gluconeogenesis (20). In contrast 
to leptin and most other adipokines, adiponectin is reduced in 
obesity and increased in response to weight loss. Furthermore, 
peripheral adiponectin treatment decreases weight and fat by 
increasing energy expenditure and fatty acid oxidation (21). 
Adiponectin levels correlate inversely with insulin resistance. 
Adiponectin-de!cient mice develop insulin resistance, dyslipi-
demia, and atherosclerosis (22). Several studies found decreased 
circulating levels of adiponectin in patients with OSA syndrome 
(23-27, 29 );  these may contribute to the development of cardio-
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metabolic complications in OSA patients. Harsh et al (23) found 
a signi!cant relation between adiponectin and the insulin sen-
sitivity index in overweight patients with OSA. During CPAP 
treatment, changes in adiponectin levels were highly predictable 
by the insulin sensitivity index. However, they failed to observe 
signi!cant changes a*er 3 months treatment. Vatansever et al 
(27) suggested that recurrent hypoxia-reoxygenation attacks in 
OSA patients may activate oxidative stress, elevating sympathet-
ic activity and leading to low levels of adiponectin. On the con-
trary, one study reported that plasma adiponectin levels were 
elevated in otherwise healthy subjects with OSA (28). 
Resistin
Circulating resistin levels were studied in patients with OSA 
and obtained results seem contradictory. One of the earliest 
studies reported that resistin levels remained unchanged a*er 
8 weeks of CPAP therapy and there was a weak negative cor-
relation between insulin sensitivity index and resistin in obese 
OSA patients (30). However, this study did not include an OSA-
negative control group and no chance to compare resistin levels 
between the patients and controls. In a following study, Yama-
moto et al (31) measured resistin levels in 31 men with OSA and 
10 men without OSA. #ese two groups were matched for age, 
body mass index and metabolic pro!le. #e authors reported 
that untreated OSA patients had a higher mean serum resistin 
level than control subjects and 3 months CPAP therapy led to 
reduction in resistin levels in the patient group. On the contrary, 
Ursavas et al (32) found no signi!cant di&erence in circulating 
resistin levels in OSA group compared to non-OSA controls, 
whereas decreased resistin levels in overweight and obese sub-
jects with OSA were reproted (33).
 Collectively, all these studies on secretory products of adipo-
cytes show us that adipocyte function alters during the course of 
sleep apnea syndrome. Yet it is not clear whether those changes 
are consequences resulting from or causes leading to the disease. 
Investigating the mechanisms of adipose tissue dysfunction in 
patients with OSA may provide us with novel targets to prevent 
its complications and also the disease itself (for resistin-targeted 
pharmacotherapy, see Gertler’s innovative review in this volume 
of Adipobiology). 
In the following section, the plausible mechanisms of adipose 
dysfunction will be discussed.
MECHANISMS OF ADIPOSE DYSFUNCTION IN OBSTRUCTIVE 
SLEEP APNEA
Hypoxia
Hypoxia is one of the hallmarks of OSA. Recurrent episodes of 
apnea or hypopnea are followed by marked transient decreases 
in arterial oxygen saturation. By the resumption of ventilation, 
blood oxygen saturation rapidly turns to normal levels. #is kind 
of hypoxia is called as intermittent hypoxia which may be quite 
distinct from sustained hypoxia mostly seen in chronic obstruc-
tive lung diseases. In addition to uctuating arterial oxygen satu-
ration during nighttime due to apneic episodes of sleep, adipose 
tissue may be a&ected from a daytime hypoxia stemming from 
obesity itself. Trayhurn (34) stated that cardiac output and blood 
ow to adipose tissue are not increased in proportion to fat mass 
in obesity. Second, diameter of adipocytes may increase up to 
150-200 mm and this is larger than normal di&usion distance of 
oxygen (i.e., 100-200 mm) (34). Taken together, both respiratory 
cessations and obesity contribute to hypoxia which may a&ect 
the secretory function of adipocytes. In fact, it has been shown 
that hypoxia inhibited the expression and secretion of adiponec-
tin in 3T3-L1 cell line which di&erentiate into an adipocyte-like 
phenotype (35). Human adipocytes were also incubated in ei-
ther 21% or 1% oxygen for 24 h and hypoxic state led to increase 
in adipokines including leptin, vascular endothelial growth fac-
tor, and interleukine-6 release (34). Finally, transcription factors 
including nuclear factor kappa B (NFκB) and hypoxia inducible 
factor (HIF)-1 implicated in the molecular response to hypoxia 
are activated in adipocytes. Studies in patients with OSA showed 
NFκB activation in circulating monocytes and neutrophils (36). 
No previous study investigated NFκB in adipocytes obtained 
from OSA patients. However, strong evidence suggest hypoxia 
as one of the main factors a&ecting adipokine production.
Oxidative stress
It is plausible to consider that hypoxia/reoxygenation episodes 
during apneas and hypopneas may lead to increased oxydative 
stress, and besides hypoxia, oxidative stress may contribute to 
adipocyte dysfunction in sleep apnea syndrome. However, the 
presence of oxidative stress in sleep apnea patients is controver-
sial. Several studies reported increased oxidative stress in pa-
tients with obstructive slep apnea. For instance, morning levels 
of oxidative stress biomarkers such as thiobarbituric acid reac-
tive substances and peroxides signi!cantly increased in patients 
with OSA (37). Superoxide generation from polymorphonuclear 
neutrophils was enhanced in OSA and e&ective CPAP treatment 
fully reversed superoxide release (38). Conversely, some other 
studies failed to !nd any evidence of increased oxidative stress 
in OSA (39-41). Oxidative stress may a&ect adipocyte physiol-
ogy. Kamigaki et al (42) examined the e&ect of hydrogen perox-
ide on the gene expressions of adiponectine, leptin and resistin. 
#ese latter authors suggested that even short-time exposure to 
oxidative stress was enough to change expression of some adi-
pokines for a long time.
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Increased sympathetic nerve activity
Adipose tissue is innervated by the sympathetic nervous system. 
Both in vitro and in vivo studies demonstrated that norepineph-
rine stimulation of WAT via b-adrenoceptors is one of the major 
stimulators of lipolysis (43). Both catecholamines from adrenal 
medulla and norepinephrine from sympathetic innervation are 
important in directing lipolysis (44). Patients with OSA have a 
high level of sympathetic nerve activity due to increased respira-
tory e&ort and arousals during sleep, and sympathetic hyperac-
tivity maintains even during daytime (45). Sympathetic activity 
may a&ect endocrine activity of the adipose cells besides meta-
bolic function, and may thus alter adipokine secretion.
 Regional body fat deposition i.e. central obesity appears 
important in OSA. #e central form of obesity contributes to 
accumulation of adipose tissue around the upper airway and 
neck which in turn reduces the diameter of upper airway and 
promotes pharyngeal collapse (46). Understanding the factors 
a&ecting preferential fat deposition and mobilization may shed 
light on elucidating the pathophysiology of airway obstruction 
in sleep apnea. One mechanism may be the di&erential accumu-
lation of lipid by adipocytes through innervation by the sympa-
thetic nervous system (47).
All roads lead to in!ammation
Although the etiology of OSA is uncertain, intense local and sys-
temic inammation are present in these patients. Hypoxia, oxi-
dative stress, and sympathetic nervous activity may contribute to 
development of inammation and adipocytes seem to occupy the 
center of these pathophysiologic pathways (Fig. 1). #e presence 
of systemic inammation is characterized by elevated levels of 
certain potent pro-inammatory mediators such as CRP, leptin, 
TNF-a, IL-1b, IL-6, and reactive oxygen species. C-reactive pro-
tein is a sensitive marker for systemic inammation. Activated 
NFκB is a key transcription factor in chronic inammatory dis-
eases. Yamauchi et al (48) have demonstrated that there was an ac-
tivation of NFκB in peripheral blood monocytes, as a representa-
tive transcription factor involved in regulating inammation, and 
there was evidence showing that this activation was functionally 
reversed by one night of CPAP titration. Apnea-induced hypoxia 
and reoxygenation, which generates reactive oxygen species, sug-
gested to activate the oxidant-sensitive, NFκB, increasing systemic 
inammation in OSA (36). As discussed, adipose cells can secrete 
both pro- and anti-inammatory adipokines (3-7). In Homo obe-
sus, secretory pro!le of adipose tissue is changed towards a proin-
ammatory pattern, which may contribute to the development of 
various diseases including OSA syndrome.
Figure 1. Mechanisms of adipose dysfunction in obstructive sleep apnea. Hypoxia and oxidative stress stemming from sleep 
disordered breathing lead to in"ammation which collectively resulted in adipose dysfunction manifested by altered adipokine 
secretion, which may contribute to the pathophysiology and cardiometabolic complications in obstructive sleep apnea. 
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Involvement of neurotrophins 
One of biggest recent achievements of neurobiology is the study 
on neurotrophic factors and the role they play in the patho-
genesis of various neurological and non-neurological diseases. 
#e neurotrophins are exciting examples of these factors. #ey 
belong to a family of proteins consisting of nerve growth fac-
tor (NGF), brain-derived neurotrophic factor (BDNF), neuro-
trophin-3 (NT-3), NT-4/5, NT-6, and NT-7. Today, NGF and 
BDNF are well recognized to mediate multiple trophobiological 
e&ects, ranging from neurotrophic through immunotrophic and 
epitheliotrophic to metabotrophic e&ects (reviewed in 49-51). 
In the same vein, recent studies in adipobiology reveal that this 
tissue, as mentioned above, is the body’s largest endocrine and 
paracrine organ producing multiple adipokines, with NGF and 
BDNF being also produced from adipose tissue (52).
Recently, some neurotrophins, particularly BDNF, enter the pic-
ture of OSA syndrome (53-59), thus providing novel pharma-
cological targets for the therapy of this syndrome (Trk A, Trk B 
receptors for NGF and BDNF, respectively). Serum and plasma 
BDNF levels in both pediatric and adult patients with untreated 
OSA syndrome were comparable to healthy peers (54, 60). In-
terestingly, treatment of OSA by adenotonsillectomy in pediatric 
patients (54) or by CPAP in adults (60) led to signi!cant decrease 
in circulating BDNF levels. Staats et al (60) suggested that im-
mediate BDNF decrease following treatment reects increased 
neuronal demand for BDNF and changed neuronal activity and 
synaptic transmission. Altered BDNF regulation may be associ-
ated with neurocognitive dysfunction in patients with OSA (56).
Coda
#e following main concusions might be extrcated form the pre-
sent review: (i) preventing and treating OSA  is a major public 
health priority, but compliance to CPAP therapy is low, (ii) al-
tered adipokine secertion homeostasis may provide a new focus 
for understanding and potentially treating OSA and its cardio-
metabolic consequences, (iii) reversing hypoxia and attenuating 
oxidative stress and inammation through HIFs or other regu-
latory factors present novel opportunities and targets in OSA 
therapy, (iv) Trk A and Trk B receptor-directed pharmacology 
may be an additional therapeutic perspective.
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